These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Effectiveness of ChAdOx1 nCOV-19 Vaccine: Experience of a tertiary care institute. Bobdey S; Kaushik SK; Sahu R; Naithani N; Vaidya R; Sharma M; Vashishtha K; Yadav AK; Sen S; Karade S Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S271-S277. PubMed ID: 34334893 [TBL] [Abstract][Full Text] [Related]
9. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959 [TBL] [Abstract][Full Text] [Related]
11. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Nordström P; Ballin M; Nordström A Lancet; 2022 Feb; 399(10327):814-823. PubMed ID: 35131043 [TBL] [Abstract][Full Text] [Related]
12. Safety, immunogenicity & effectiveness of the COVID-19 vaccine among healthcare workers in a tertiary care hospital. Kataria S; Sharma P; Singh MK; Deswal V; Kumar K; Alam S; Gupta V; Phogat R; Sarma S; Patil N; Dutt R; Singh P; Saxena R; Trehan N Indian J Med Res; 2022; 155(5&6):518-525. PubMed ID: 36348600 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ; Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study. Pramod S; Govindan D; Ramasubramani P; Kar SS; Aggarwal R; Vaccine; 2022 May; 40(24):3294-3297. PubMed ID: 35168838 [TBL] [Abstract][Full Text] [Related]
15. Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study. Jose D; Dhupdale N; Cacodcar JA; Kamat U Curr Drug Saf; 2023; 18(4):516-527. PubMed ID: 35927820 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study. Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496 [TBL] [Abstract][Full Text] [Related]
17. Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis. Meeraus W; de Munter L; Gray CM; Dwivedi A; Wyndham-Thomas C; Ouwens M; Hartig-Merkel W; Drikite L; Rebry G; Carmona A; Stuurman AL; Chi Nguyen TY; Mena G; Mira-Iglesias A; Icardi G; Otero-Romero S; Baumgartner S; Martin C; Taylor S; Bollaerts K Lancet Reg Health Eur; 2023 Aug; 31():100675. PubMed ID: 37547274 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study. Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]